Tesamorelin vs NAD+ (Nicotinamide Adenine Dinucleotide)
Head-to-head comparison of Tesamorelin and NAD+ (Nicotinamide Adenine Dinucleotide) for research applications. Both peptides are studied for various research applications, but they differ significantly in mechanism and evidence level.
Side-by-Side Comparison
| Attribute | Tesamorelin | Nad Plus |
|---|---|---|
| Category | Growth Hormone Secretagogue | Anti-Aging / Telomere |
| Mechanism | Tesamorelin binds to and stimulates human GRF (growth hormone-releasing factor) receptors on the anterior pituitary with similar potency as endogenous GRF, stimulating synthesis and release of endogenous growth hormone. | Functions as: (1) an electron carrier in glycolysis, TCA cycle, and oxidative phosphorylation; (2) a substrate for sirtuins (SIRT1-7), which regulate gene expression, DNA repair, and metabolism; (3) a substrate for PARPs, which repair DNA damage; (4) a substrate for CD38/CD157, involved in calcium signaling and immune function. |
| Evidence Rating | A — FDA Approved | C — Early Human / Mixed Evidence |
| Clinical Status | FDA-approved (Egrifta SV 2019, Egrifta WR March 2025) for HIV-associated lipodystrophy | NAD+ IV: used clinically at anti-aging and addiction clinics; no FDA approval. NMN: Phase I/II human trials completed (Yoshino et al., Science 2021). NR: multiple human trials completed. |
| Safety Profile | Headache, nausea, and flu-like symptoms reported; May increase blood glucose -- monitoring recommended in diabetics | IV NAD+: commonly causes flushing, nausea, chest tightness, abdominal cramping during infusion — dose-rate dependent; Rare tachycardia and blood pressure changes during IV infusion |
| Molecular Weight | ~5135.9 g/mol | 663.43 g/mol |
| Half-Life | ~26–38 minutes | ~30 minutes (IV plasma); intracellular NAD+ turnover ~6-10 hours |
Overview
Tesamorelin and NAD+ (Nicotinamide Adenine Dinucleotide) are both research peptides studied across multiple applications. This comparison examines their mechanisms, evidence base, and safety profiles to help researchers understand the key differences and overlaps.
Tesamorelin — Mechanism & Evidence
It stimulates endogenous GH and IGF-1 production. Phase 3 trials demonstrated significant visceral fat reduction with a generally well-tolerated safety profile over 26 weeks of therapy.
Key claims: Reduces visceral adipose tissue in HIV lipodystrophy; Increases skeletal muscle area and density; Effective on INSTI-based HIV regimens.
Tesamorelin 10mg
10mg
NAD+ (Nicotinamide Adenine Dinucleotide) — Mechanism & Evidence
NAD+ is a fundamental coenzyme present in all living cells that serves as a critical electron carrier in metabolic reactions and a substrate for enzymes including sirtuins, PARPs, and CD38. NAD+ levels decline approximately 50% between ages 40 and 60. While not a peptide, NAD+ and its precursors (NMN, NR) are frequently discussed in peptide communities. IV NAD+ infusions are popular at anti-aging clinics, though large-scale human efficacy trials are limited.
Key claims: IV NAD+ restores youthful cellular function; NAD+ precursors (NMN/NR) slow aging; Helps with addiction and withdrawal.
Shared Research Applications
These peptides target different research areas. Tesamorelin focuses on Body Composition, while NAD+ (Nicotinamide Adenine Dinucleotide) targets Anti-Aging & Longevity, Metabolic Health.
Safety Considerations
Tesamorelin: Headache, nausea, and flu-like symptoms reported May increase blood glucose -- monitoring recommended in diabetics FDA pregnancy category X -- tesamorelin can harm an unborn baby or cause birth defects
NAD+ (Nicotinamide Adenine Dinucleotide): IV NAD+: commonly causes flushing, nausea, chest tightness, abdominal cramping during infusion — dose-rate dependent Rare tachycardia and blood pressure changes during IV infusion Theoretical concern: NAD+ is used by cancer cells; boosting NAD+ in the presence of occult malignancy could promote tumor progression
Shop Research Peptides
Tesamorelin 10mg
10mg
BPC-157 5mg
5mg
Retatrutide 20mg
20mg
Retatrutide 10mg
10mg
GHK-Cu 50mg
50mg
Quality Documentation
Review batch documentation before making research purchasing decisions. Volta pairs product education with COA literacy so researchers can evaluate purity, identity, lot details, and testing context.
Product cards on this page link to current catalog entries and available quality documentation.
Related Research News
Tesamorelin vs CJC-1295: Evidence Gaps and Data
No head-to-head trial compares tesamorelin and CJC-1295. Existing evidence is analytical, not clinical, leaving efficacy claims unsupported.
Tesamorelin vs Ipamorelin: Evidence, Uses, Risks
This article compares tesamorelin and ipamorelin based on published human evidence, highlighting what is known about their uses and risks and where direct comparative data is missing.
Tesamorelin Research Interest Grows Among Synthetic GHRPs
Synthetic growth hormone-releasing peptides (GHRPs) are drawing increasing attention in scientific research, with tesamorelin emerging as a focal point. The compound, a synthetic analog of growth hormone-releasing hormone, is being studied for its potential to modulate growth hormone levels. This article examines the rising research interest in tesamorelin and its place within the broader class of synthetic GHRPs.